Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort
Liver International · 2026
DOI: 10.1111/liv.70561 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Fanpu Ji und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Antiviral Agents, Liver Cirrhosis, Hepatitis C, Chronic. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background & Aims Direct‐acting antiviral agents (DAA)‐mediated HCV cure correlates with better outcomes, but there are insufficient data on detailed mortality‐related risk factors after cure. This study sought to clarify mortality and associated risk factors post‐HCV cure.
Methods
The study included HCV patients with sustained virological response following DAA (DAA‐SVR) from 39 REAL‐C centres in North America, Europe and Asia‐Pacific. The primary outcome was all‐cause mortality in DAA‐SVR patients. Mortality rate per 1000 patient‐years (PY) was calculated as the number of deaths divided by total PY multiplied by 1000.
Results
A total of 10 034 DAA‐SVR patients (stratified by cirrhosis status: 5611 non‐cirrhosis, 4153 compensated, 270 decompensated) were included. With a median follow‐up of 4.76 PY, 4.9% (491) died. The all‐cause mortality rates were 6.2, 13.1, 60.0 and 10.4 per 1000 PY for patients without cirrhosis, compensated and decompensated cirrhosis, and overall patients, respectively. The 5‐year cumulative survival was 95.1% (94.5%–95.6%) overall, with the lowest rate of 73.9% (67.0%–79.5%) in decompensated cirrhosis. Non‐liver‐related death was the main cause in non‐cirrhosis (non‐liver‐related vs. liver: 5.2 vs. 0.8 per 1000 PY)/compensated cirrhosis (8.2 vs. 4.8 per 1000 PY), while liver‐related death was dominant in decompensated cirrhosis (24.7 vs. 33.8 per 1000 PY). Risk factors for higher mortality included age > 65 (3.2‐fold), male (1.5‐fold), cirrhosis (decompensated 7.6‐fold) and baseline DM (1.5‐fold).
Conclusion
This study showed significant age, sex, fibrosis stage and DM differences in mortality and causes among DAA‐SVR patients. It provided granular subgroup data for precision medicine to support individualised care, future modelling studies and public health planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA.
- Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
- Department of Transfusion Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
ORCID-Profile: Fanpu Ji, Hidenori Toyoda, Chung-Feng Huang, Yu Jun Wong, Masanori Atsukawa, Yao-Chun Hsu, Dae Won Jun, Cheng-Hao Tseng, Masatoshi Ishigami, Takashi Honda, Tsunemasa Watanabe, Toru Ishikawa, Hiroaki Haga, Hirokazu Takahashi, Jia Li, Rui Huang, Grace Lai-Hung Wong, Qing Ye, Sang Bong Ahn, Sung-Eun Kim, Gi-Ae Kim, Soung Won Jeong, Hyunwoo Oh, Satoshi Yasuda
Förderung
- Gilead Sciences
Zitieren
APA
Ji, F., Tran, S., Toyoda, H., Enomoto, M., Ogawa, E., Suzuki, T., Huang, C. F., Wong, Y. J., Chuma, M., Uojima, H., Atsukawa, M., Hsu, Y. C., Jun, D. W., Nozaki, A., Tseng, C. H., Ishigami, M., Honda, T., Trinh, H., Watanabe, T., …, & Gao, X. (2026). Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort. Liver International. https://doi.org/10.1111/liv.70561
Vancouver
Ji F, Tran S, Toyoda H, Enomoto M, Ogawa E, Suzuki T, et al. Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort. Liver International. 2026. doi:10.1111/liv.70561
BibTeX
@article{Ji2026,
author = {Ji, Fanpu and Tran, Sally and Toyoda, Hidenori and Enomoto, Masaru and Ogawa, Eiichi and Suzuki, Takanori and Huang, Chung-Feng and Wong, Yu Jun and Chuma, Makoto and Uojima, Haruki and Atsukawa, Masanori and Hsu, Yao-Chun and Jun, Dae Won and Nozaki, Akito and Tseng, Cheng-Hao and Ishigami, Masatoshi and Honda, Takashi and Trinh, Huy and Watanabe, Tsunemasa and Abe, Hiroshi and Preda, Carmen and Lee, Dong Hyun and Ishikawa, Toru and Haga, Hiroaki and Liang, Jing and Takahashi, Hirokazu and Vutien, Phillip and Landis, Charles and Li, Jia and Takaguchi, Koichi and Senoh, Tomonori and Huang, Rui and Wong, Grace Lai-Hung and Wong, Vincent Wai-Sun and Lam, Carla Pui-Mei and Huang, Daniel Q and Asai, Akira and Ye, Qing and Do, Ai-Thien and Do, Son and Itokawa, Norio and Nakamuta, Makoto and Nomura, Hideyuki and Kajiwara, Eiji and Azuma, Koichi and Dohmen, Kazufumi and Kawano, Akira and Koyanagi, Toshimasa and Ooho, Aritsune and Satoh, Takeaki and Takahashi, Kazuhiro and Yoon, Eileen L and Ahn, Sang Bong and Jung, Jang Han and Kim, Sung-Eun and Kim, Gi-Ae and Jeong, Soung Won and Oh, Hyunwoo and Yasuda, Satoshi and Gao, Xu},
title = {Long‐Term Mortality Following Hepatitis C Cure in a Real‐World Multinational Cohort},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70561}
}
EUVIMED